Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 7, 2025

Histone deacetylases (HDACs) are a class of epigenetic regulators that play pivotal roles in key biological processes such as cell proliferation, differentiation, metabolism, and immune regulation. Based on this, HDAC inhibitors (HDACis), novel epigenetic-targeted therapeutic agents, have demonstrated significant antitumor potential by inducing cycle arrest, activating apoptosis, modulating the microenvironment. Current research is focused developing highly selective isoform combination therapy strategies tailored to molecular subtypes, aiming overcome off-target effects resistance issues associated with traditional broad-spectrum inhibitors. This review systematically elaborates multidimensional regulatory networks HDACs tumor malignancy assesses clinical translation progress next-generation HDACis their prospects precision medicine, providing theoretical framework strategic reference for development drugs.

Language: Английский